Israel based Teva Pharmaceutical has launched generic equivalent of Intuniv (guanfacine), nonstimulant medication for the treatment of attention deficit hyperactivity disorder (ADHD), in US.
ADHD is the most common neurobehavioral disorder diagnosed in children in the United States. ADHD affects 1 in 10 U.S. children and half of these children are diagnosed by the age of six.
"Guanfacine extended-release tablets join Teva's current generic line of seven ADHD products," commented Mr Brendan O'Grady, president and CEO, North America Generic Medicines. "We recognize the need to make affordable generic treatment options available to patients with ADHD."
Intuniv (guanfacine) had total market sales of approximately $804 million in the United States, according to IMS data as of March 2015.
